Activation of Rho kinase isoforms in lung endothelial cells during inflammation

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 2385-2394

  Mong, Phyllus Y ^a   Wang, Qin ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FASUDIL; LIPOPOLYSACCHARIDE; MYOSIN LIGHT CHAIN; RHO KINASE; RHO KINASE 1; RHO KINASE 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ENZYME INHIBITOR; ISOENZYME; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; LUNG BLOOD VESSEL; LUNG ENDOTHELIUM; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STRESS FIBER; VASCULAR ENDOTHELIUM; ANIMAL; DRUG EFFECT; ENDOTHELIUM CELL; ENZYMOLOGY; FLOW CYTOMETRY; IMMUNOLOGY; LUNG; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; ENDOTHELIAL CELLS; ENZYME ACTIVATION; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; INFLAMMATION; ISOENZYMES; LUNG; MICE; MYOSIN LIGHT CHAINS; PHOSPHORYLATION; RHO-ASSOCIATED KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 61449149438     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802811     Document Type: Article

References (51)

1. Loirand, G., P. Guérin, and P. Pacaud. 2006. Rho kinases in cardiovascular physiology and pathophysiology. Circ. Res. 98: 322-334.
2. Olson, M. F. 2008. Applications for ROCK kinase inhibition. Curr. Opin. Cell. Biol. 20: 242-248.
3. Lowery, D. M., K. R. Clauser, M. Hjerrild, D. Lim, J. Alexander, K. Kishi, S. E. Ong, S. Gammeltoft, S. A. Carr, and M. B. Yaffe. 2007. Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J. 26: 2262-2273.
4. Lee, H. H., and Z. F. Chang. 2008. Regulation of RhoA-dependent ROCKII activation by Shp2. J. Cell Biol. 181: 999-1012.
5. Sebbagh, M., C. Renvoize, J. Hamelin, N. Riche, J. Bertoglio, and J. Breard. 2001. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat. Cell Biol. 3: 346-352.
6. Sebbagh, M., J. Hamelin, J. Bertoglio, E. Solary, and J. Breard. 2005. Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. J. Exp. Med. 201: 465-471.
7. Thumkeo, D., J. Keel, T. Ishizaki, M. Hirose, K. Nonomura, H. Oshima, M. Oshima, M. M. Taketo, and S. Narumiya. 2003. Targeted disruption of the mouse rho-associated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol. Cell. Biol. 23: 5043-5055.
8. Thumkeo, D., Y. Shimizu, S. Sakamoto, S. Yamada, and S. Narumiya. 2005. ROCK-I and ROCK-II cooperatively regulate closure of eyelid and ventral body wall in mouse embryo. Genes Cells 10: 825-834.
9. Shimizu, Y., D. Thumkeo, J. Keel, T. Ishizaki, H. Oshima, M. Oshima, Y. Noda, F. Matsumura, M. M. Taketo, and S. Narumiya. 2005. ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J. Cell Biol. 168: 941-953.
10. Noma, K., Y. Rikitake, N. Oyama, G. Yan, P. Alcaide, P. Y. Liu, H. Wang, D. Ahl, N. Sawada, R. Okamoto, et al. 2008. ROCK1 mediates leukocyte recruitment and neointima formation following vascular injury. J. Clin. Invest. 118: 1632-1644.
11. Liao, J. K., M. Seto, and K. Noma. 2007. Rho kinase (ROCK) inhibitors. J. Cardiovasc. Pharmacol. 50: 17-24.
12. Mohri, M., H. Shimokawa, Y. Hirakawa, A. Masumoto, and A. Takeshita. 2003. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J. Am. Coll. Cardiol. 41: 15-19.
13. Chen, W., S. Pendyala, V. Natarajan, J. G. Garcia, and J. R. Jacobson. 2008. Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition. Am. J. Physiol. 295: L575-L583.
14. Tasaka, S., H. Koh, W. Yamada, M. Shimizu, Y. Ogawa, N. Hasegawa, K. Yamaguchi, Y. Ishii, S. E. Richer, C. M. Doerschuk, and A. Ishizaka. 2005. Attenuation of endotoxin-induced acute lung injury by the Rho-associated kinase inhibitor, Y-27632. Am. J. Respir. Cell. Mol. Biol. 32: 504-510.
15. Mong, P., C. Petrulio, H. L. Kaufman, and Q. Wang. 2008. Activation of Rho kinase by TNF-α is required for JNK activation in human pulmonary microvascular endothelial cells. J. Immunol. 180: 550-558.
16. Marelli-Berg, F. M., E. Peek, E. A. Lidington, H. J. Stauss, and R. I. Lechler. 2000. Isolation of endothelial cells from murine tissue. J. Immunol. Methods 244: 205-215.
17. Li, C., R. Issa, P. Kumar, I. N. Hampson, J. M. Lopez-Novoa, C. Bernabeu, and S. Kumar. 2003. CD105 prevents apoptosis in hypoxic endothelial cells. J. Cell. Sci. 116: 2677-2685.
18. Shimokawa, H., M. Seto, N. Katsumata, M. Amano, T. Kozai, T. Yamawaki, K. Kuwata, T. Kandabashi, K. Egashira, I. Ikegaki, et al. 1999. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc. Res. 43: 1029-1039.
19. Tamura, M., H. Nakao, H. Yoshizaki, M. Shiratsuchi, H. Shigyo, H. Yamada, T. Ozawa, J. Totsuka, and H. Hidaka. 2005. Development of specific Rho-kinase inhibitors and their clinical application. Biochim. Biophys. Acta 1754: 245-252.
20. McKinsey, T. A., and D. A. Kass. 2007. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat. Rev. Drug Discov. 6: 617-635.
21. Higashi, M., H. Shimokawa, T. Hattori, J. Hiroki, Y. Mukai, K. Morikawa, T. Ichiki, S. Takahashi, and A. Takeshita. 2003. Long-term inhibition of Rhokinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ. Res. 93: 767-775.
22. Hattori, T., H. Shimokawa, M. Higashi, J. Hiroki, Y. Mukai, K. Kaibuchi, and A. Takeshita. 2004. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ. Res. 94: 46-52.
23. Hattori, T., H. Shimokawa, M. Higashi, J. Hiroki, Y. Mukai, H. Tsutsui, K. Kaibuchi, and A. Takeshita. 2004. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109: 2234-2239.
24. Abe, K., H. Shimokawa, K. Morikawa, T. Uwatoku, K. Oi, Y. Matsumoto, T. Hattori, Y. Nakashima, K. Kaibuchi, K. Sueishi, and A. Takeshit. 2004. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ. Res. 94: 385-393.
25. McKenzie, J. A., and A. J. Ridley. 2007. Roles of Rho/ROCK and MLCK in TNF-α-induced changes in endothelial morphology and permeability. J. Cell. Physiol. 213: 221-228.
26. Ito, M., T. Nakano, F. Erdodi, and D. J. Hartshorne. 2004. Myosin phosphatase: structure, regulation and function. Mol. Cell. Biochem. 259: 197-209.
27. Yoneda, A., D. Ushakov, H. A. Multhaupt, and J. R. Couchman. 2007. Fibronectin matrix assembly requires distinct contributions from Rho kinases I and II. Mol. Biol Cell. 18: 66-75.
28. Yoneda, A., H. A. Multhaupt, and J. R. Couchman. 2005. The Rho kinases I and II regulate different aspects of myosin II activity. J. Cell Biol. 170: 443-453.
29. Seybold, J., D. Thomas, M. Witzenrath, S. Boral, A. C. Hocke, A. Bürger, A. Hatzelmann, H. Tenor, C. Schudt, M. Krüll, et al. 2005. Tumor necrosis factor-α-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 105: 3569-3576.
30. Mehta, D., and A. B. Malik. 2006. Signaling mechanisms regulating endothelial permeability. Physiol. Rev. 86: 279-367.
31. Xu, M., C. L. Waters, C. Hu, R. B. Wysolmerski, P. A. Vincent, and F. L. Minnear. 2007. Sphingosine 1-phosphate rapidly increases endothelial barrier function independently of VE-cadherin but requires cell spreading and Rho kinase. Am. J. Physiol. 293: C1309-C1318.
32. Knezevic, N., A. Roy, B. Timblin, M. Konstantoulaki, T. Sharma, A. B. Malik, and D. Mehta. 2007. GDI-1 phosphorylation switch at serine 96 induces RhoA activation and increased endothelial permeability. Mol. Cell. Biol. 27: 6323-6333.
33. Gorovoy, M., R. Neamu, J. Niu, S. Vogel, D. Predescu, J. Miyoshi, Y. Takai, V. Kini, D. Mehta, A. B. Malik, and T. Voyno-Yasenetskaya. 2007. RhoGDI-1 modulation of the activity of monomeric RhoGTPase RhoA regulates endothelial barrier function in mouse lungs. Circ. Res. 101: 50-58.
34. Vandenbroucke, E., D. Mehta, R. Minshall, and A. B. Malik. 2008. Regulation of endothelial junctional permeability. Ann. NY Acad. Sci. 1123: 134-145.
35. Nwariaku, F. E., P. Rothenbach, Z. Liu, X. Zhu, R. H. Turnage, and L. S. Terada. 2003. Rho inhibition decreases TNF-induced endothelial MAPK activation and monolayer permeability. J. Appl. Physiol. 95: 1889-1895.
36. Petrache, I., A. D. Verin, M. T. Crow, A. Birukova, F. Liu, and J. G. Garcia. 2001. Differential effect of MLC kinase in TNF-α-induced endothelial cell apoptosis and barrier dysfunction. Am. J. Physiol. 280: L1168-L1178.
37. van Nieuw Amerongen, G. P., C. M. Beckers, I. D. Achekar, S. Zeeman, R. J. Musters, and V. W. van Hinsbergh. 2007. Involvement of Rho kinase in endothelial barrier maintenance. Arterioscler. Thromb. Vasc. Biol. 27: 2332-2339.
38. Baumer, Y., S. Burger, F. E. Curry, N. Golenhofen, D. Drenckhahn, and J. Waschke. 2008. Differential role of Rho GTPases in endothelial barrier regulation dependent on endothelial cell origin. Histochem. Cell. Biol. 129: 179-191.
39. Riento, K., R. M. Guasch, R. Garg, B. Jin, and A. J. Ridley. 2003. RhoE binds to ROCK I and inhibits downstream signaling. Mol. Cell. Biol. 23: 4219-4229.
40. Riento, K., N. Totty, P. Villalonga, R. Garg, R. Guasch, and A. J. Ridley. 2005. RhoE function is regulated by ROCK I-mediated phosphorylation. EMBO J. 24: 1170-1180.
41. Pinner, S., and E. Sahai. 2008. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat. Cell. Biol. 10: 127-137.
42. Jeyaseelan, S., R. Manzer, S. K. Young, M. Yamamoto, S. Akira, R. J. Mason, and G. S. Worthen. 2005. Toll-IL-1 receptor domain-containing adaptor protein is critical for early lung immune responses against Escherichia coli lipopolysaccharide and viable Escherichia coli. J. Immunol. 175: 7484-7495.
43. Noulin, N., V. F. Quesniaux, S. Schnyder-Candrian, B. Schnyder, I. Maillet, T. Robert, B. B. Vargaftig, B. Ryffel, and I. Couillin. 2005. Both hemopoietic and resident cells are required for MyD88-dependent pulmonary inflammatory response to inhaled endotoxin. J. Immunol. 175: 6861-6869.
44. Greenwood, J., C. L. Amos, C. E. Walters, P. O. Couraud, R. Lyck, B. Engelhardt, and P. Adamson. 2003. Intracellular domain of brain endothelial intercellular adhesion molecule-1 is essential for T lymphocyte-mediated signaling and migration. J. Immunol. 171: 2099-2108.
45. Saito, H., Y. Minamiya, S. Saito, and J. Ogawa. 2002. Endothelial Rho and Rho kinase regulate neutrophil migration via endothelial myosin light chain phosphorylation. J. Leukocyte Biol. 72: 829-836.
46. Breslin, J. W., H. Sun, W. Xu, C. Rodarte, A. B. Moy, M. H. Wu, and S. Y. Yuan. 2006. Involvement of ROCK-mediated endothelial tension development in neutrophil-stimulated microvascular leakage. Am. J. Physiol. 290: H741-H750.
47. Jones, S. A. 2005. Directing transition from innate to acquired immunity: defining a role for IL-6. J. Immunol 175: 3463-3468.
48. Fielding, C. A., R. M. McLoughlin, L. McLeod, C. S. Colmont, M. Najdovska, D. Grail, M. Ernst, S. A. Jones, N. Topley, and B. J. Jenkins. 2008. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J. Immunol. 181: 2189-2195.
49. Liu, L., B. R. Schwartz, N. Lin, R. K. Winn, and J. M. Harlan. 2002. Requirement for RhoA kinase activation in leukocyte de-adhesion. J. Immunol. 169: 2330-2336.
50. Gebb, S., and T. Stevens. 2004. On lung endothelial cell heterogeneity. Microvasc. Res. 68: 1-12.
51. 2+ channels and pulmonary endothelial permeability: insights from study of intact lung and chronic pulmonary hypertension. Microcirculation 13: 725-739.